http://repository.usmf.md:80/handle/20.500.12710/18167 The Annual Scientific Conference of Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova on the occasion of the 76 years of activity: Research in biomedicine and health quality, excellence and performance, 20-22 October 2021 Sun, 12 Apr 2026 04:17:13 GMT 2026-04-12T04:17:13Z http://repository.usmf.md:80/handle/20.500.12710/18196 Title: The Moldovan Medical Journal. October 2021, Vol. 64, No 4 Abstract: The Moldovan Medical Journal is an international scientific double-blind peer-reviewed periodical edition, 4 per year, of the Scientific Medical Association of the Republic of Moldova designed for specialists in the areas of medicine, dentistry, pharmacy, social medicine, and public health. From its debut, the journal has striven to support the interests of Moldovan medicine concerning the new concepts of its development. The Editorial Board warmly welcomes both the readers of and the authors of the journal, all those who are enthusiastic about searching for new and more effective ways of solving numerous medical problems. We hope that those who want to make their contribution to the science of medicine will find our journal helpful and encouraging. Fri, 01 Jan 2021 00:00:00 GMT http://repository.usmf.md:80/handle/20.500.12710/18196 2021-01-01T00:00:00Z http://repository.usmf.md:80/handle/20.500.12710/18195 Title: Drug-resistant epilepsy: modern concepts, integrative mechanisms, and therapeutic advances Authors: Chiosa, Vitalie; Ciolac, Dumitru; Chelban, Viorica; Gasnas, Daniela; Vataman, Anatolie; Munteanu, Cristina; Groppa, Stanislav Abstract: Background: Drug-resistant epilepsy is the cause of severe disability. Multiple questions remain unanswered both in terms of pathogenesis and therapeutic management. For this narrative review, PubMed database and Infomedica library were searched by using “drug-resistance in epilepsy” and “treatment of drug-resistant epilepsy” as key words. The following filters were applied: “Clinical Trial”, “Meta-analysis”, “Multicenter Study”, and “Randomized Controlled Trial”, covering the period of 01.01.2005–06.01.2021.Several hypotheses have been proposed, i.e., pharmacokinetic, intrinsic severity, gene, target, transporter, and neural network hypotheses. Many controlled trials showed different results in terms of seizure control after combined methods of therapies. Immunotherapy, palliative epilepsy surgery alone or associated with neurostimulation procedures including vagus nerve, trigeminal nerve, or deep brain stimulation may be efficient, however, seizure freedom is not always achieved. Genetic epilepsies might benefit from gene and exosome therapy; however, further studies are needed to verify their safety. Conclusions: Neuroscience of drug-resistant epilepsy faces many challenges. Inflammatory mediators, biomarkers, and genes might allow the identification of new treatment targets, contribute to an earlier diagnosis, and assess the clinical outcomes. Fri, 01 Jan 2021 00:00:00 GMT http://repository.usmf.md:80/handle/20.500.12710/18195 2021-01-01T00:00:00Z http://repository.usmf.md:80/handle/20.500.12710/18194 Title: Environmental toxic factors and clinical pattern of Parkinson’s disease Authors: Rotaru, Lilia Abstract: Background: Parkinson’s disease (PD) – the most common neuro-degenerative movement disorder – is considered a result of a multifactorial pathogenic process modulated by cumulative and interactive effects of genes and exposures. An environmental exposure could enhance or create dopaminergic neurons vulnerability and increase PD risk. The purpose of the study was to find if excessive exposure to toxic environmental factors may influence clinical pattern of PD. Material and methods: The study was conducted on 111 patients diagnosed with PD, study group being defined as PD exposed to toxins (33 patients), control group including PD patients without toxin exposure (78 patients). General epidemiological data and clinical data were recorded. Results: Toxin exposure was found in 33 patients (29.73%), more of them – men and rural residents. Toxin exposed PD patients had an insignificantly younger age. The most common disease phenotype in the study group was the akinetic-rigid phenotype (64.7%, p = 0.040), bradykinesia being the most common sign at the disease onset (57.6%, p = 0.008). Levodopa equivalent daily dose also was higher in the study group (659.02 ± 232.46, p = 0.042). Conclusions: Excessive exposure to toxic environmental factors may influence the clinical pattern of PD. In this study the akinetic-rigid type was the predominant disease phenotype associated with toxin exposure. Doses needed for treatment were higher in PD patients exposed to toxins, as an indicator of a more severe motor impairment in this group. Fri, 01 Jan 2021 00:00:00 GMT http://repository.usmf.md:80/handle/20.500.12710/18194 2021-01-01T00:00:00Z http://repository.usmf.md:80/handle/20.500.12710/18193 Title: Low-dose anticholinergic therapy causes cognitive impairment in Parkinson’s disease patients Authors: Gavriliuc, Olga; Andrușca, Alexandru; Popil, Lilian; Gavriliuc, Mihail Abstract: Background: Before L-Dopa’s discovery, anticholinergic drugs were among the first treatments for Parkinson’s disease. Only now trihexyphenidyl (THP) is approved to treat unresponsive L-dopa tremors in young, cognitively unaffected Parkinson’s disease patients. However, there are no specific recommendations for disease duration, medication dose, or cognitive status. In low-income countries, THP is still frequently used in Parkinson’s disease patients with tremor. The objective of the current study was to evaluate cognitive performance in Parkinson’s disease patients receiving a low dose of THP. Material and methods: The study was performed on nineteen PD patients, nine of whom were on THP. All patients completed MoCA cognitive assessment. The patients were matched depending on their age, disease severity based on UPDRS III and duration of the disease. Results: The THP patients were taking an average dose of 3.3 mg of THP daily for an average of 1.8 years. There were no statistical differences between THP patients and non-THP patients in age (64.8± 4.8 vs 67.2±6.9, p=0.4), UPDRS III (32.1±8.9 vs 41.5±20.6, p=0.2) and disease duration (6.2±4.9 vs 7.0 ± 4.0, p=0.7). The THP patients had lower cognitive performance, with a total MoCA of 19.22 ± 3.3 vs. non-THP patients 24.2±3.0, p=0.003. Conclusions: In Parkinson’s disease patients, even a low dose of THP causes significant cognitive loss. Fri, 01 Jan 2021 00:00:00 GMT http://repository.usmf.md:80/handle/20.500.12710/18193 2021-01-01T00:00:00Z